Capitalizing Life Science Innovations

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 to 15.

H.C. Wainwright 23rd Annual Investment Conference
Date: Monday, September 13th
Time: 7:00 a.m. ET
Location: Webcast link or at the company’s website.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit

Investor Contact: 
Daniel Ferry 
LifeSci Advisors 
+1 617-430-7576 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

NeuBase Media Information:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
This email address is being protected from spambots. You need JavaScript enabled to view it.

Zyversa Logo

Source: NeuBase Therapeutics, Inc.